Condition (MeSH)
Arenaviridae Infections
ClinicalTrials.gov lists 20 trials for Arenaviridae Infections or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 of the 20 trials are tagged with Arenaviridae Infections itself; the rest are tagged with a narrower condition beneath it.
When did Arenaviridae Infections trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2024 | 2 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 5 |
| 2018 | 1 |
| 2014 | 1 |
| 2009 | 1 |
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Arenaviridae Infections trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Observational | 7 |
How many Arenaviridae Infections trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Completed | 9 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Arenaviridae Infections trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bernhard Nocht Institute for Tropical Medicine | 2 |
| Inovio Pharmaceuticals | 2 |
| International AIDS Vaccine Initiative | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Arisan Therapeutics, Inc. | 1 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Arenaviridae Infections? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| AVIGAN | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ribavirine | 6 |
| Dexamethasone/Dexamethasone acetate | 2 |
| INO-4500 | 2 |
| HDCV Comparator | 1 |
| Day 1 Higher Dose (1×107 pfu) | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Arenaviridae Infections? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. | The Journal of clinical investigation | 2013 | Yes |
| Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. | Nature medicine | 2009 | Yes |
| In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. | Antimicrobial agents and chemotherapy | 2007 | Yes |
| Commensal bacteria calibrate the activation threshold of innate antiviral immunity. | Immunity | 2012 | No |
| Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. | Nature medicine | 2008 | No |
Showing 5 of 7 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.